Expression of iNOS - A favourable prognostic marker for early-stage carcinoma of the uterine cervix

Anticancer Research

Volumn 31, Issue 6, 2011, Pages 2319-2325

  Eggen, Tormod ^a   Sager, Georg ^b   Arnes, Marit ^b   Pettersen, Inger ^a   Ørbo, Anne ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Cervical carcinoma; Guanylyl cyclase; iNOS; Phosphodiesterase; Prognosis

Indexed keywords

CYCLIC GMP; GUANYLATE CYCLASE; GUANYLATE CYCLASE ALPHA 1; GUANYLATE CYCLASE ALPHA 2; INDUCIBLE NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GROWTH; CANCER RELAPSE; CELL INFILTRATION; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; UTERINE CERVIX CARCINOMA;

EID: 79960470953     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001.
2. Kosary CL: FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 10: 31-46, 1994.
3. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT and Major F: Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 38: 352-357, 1990. (Pubitemid 20362555)
4. Zaino RJ, Ward S, Delgado G, Bundy B, Gore H, Fetter G, Ganjei P and Frauenhoffer E: Histopathologic predictors of the behavior of surgically treated stage IB squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. Cancer 69: 1750-1758, 1992.
5. Stendahl U, Willen H and Willen R: Classification and grading of invasive squamous cell carcinoma of the uterine cervix. Acta Radiol Oncol Radiat Phys Biol 18: 481-496, 1979.
6. Willen R, Trope C, Langstrom E, Ranstam J, Killander D and Clase L: Prospective malignancy grading and flow cytometry DNA distribution in biopsy specimens from invasive squamous cell carcinoma of the uterine cervix. Anticancer Res 7: 235-242, 1987. (Pubitemid 17117949)
7. Eggen T, Arnes M, Moe B, Straume B and Orbo A: Prognosis of early cervical cancer (FIGO stages IA2, IB, and IIA) in northern Norway predicted by malignancy grading score and objective morphometric image analysis. Int J Gynecol Pathol 26: 447-456, 2007. (Pubitemid 47476332)
8. Gaarenstroom KN, Bonfrer JM, Korse CM, Renter GG and Kenemans P: Value of CYFRA 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer. Anticancer Res 17: 2955-2958, 1997.
9. Juang CM, Wang PH, Yen MS, Lai CR, Ng HT and Yuan CC: Application of tumour markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix. Gynecol Oncol 76: 103-106, 2000.
10. Orbo A, Hanevik M, Jaeger R, van Heusden S and Sager G: Urinary cyclic GMP after treatment of gynecological cancer. A prognostic marker of clinical outcome. Anticancer Res 27: 2591-2596, 2007.
11. Turner GA, Ellis RD, Guthrie D, Latner AL, Ross WM and Skillen AW: Cyclic GMP in urine to monitor the response to ovarian cancer to therapy. Br J Obstet and Gynaecol 89: 760-764, 1982.
12. Luesley DM, Blackledge GR, Chan KK and Newton JR: Random urinary cyclic 3′,5′-guanosine monophosphate in epithelial ovarian cancer: relation to other prognostic variables and to survival. Br J Obstet and Gynaecol 93: 380-385, 1986. (Pubitemid 16106876)
13. Luesley DM, Chan KK, Newton JR and Blackledge GR: Serial urinary cyclic guanosine monophosphate measurements in the assessment of response to treatment in epithelial ovarian cancer. Br J Obstet and Gynaecol 94: 461-466, 1987. (Pubitemid 17071026)
14. Turner GA, Greggi S, Guthrie D, Benedetti PP, Ellis RD, Scambia G and Mancuso S: Monitoring ovarian cancer using urine cyclic GMP. A two-centre study. Eur J Gynaecol Oncol 11: 421-427, 1990.
15. Orbo A, Jaeger R and Sager G: Urinary levels of cyclic guanosine monophosphate (cGMP) in patients with cancer of the uterine cervix: a valuable prognostic factor of clinical outcome? Eur J Cancer 34: 1460-1462, 1998. (Pubitemid 28370941)
16. Sager G and Ravna AW: Cellular Efflux of cAMP and cGMP - A question about selectivity. Mini Rev Med Chem 9: 1009-1013, 2009.
17. Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V and Moncada S: Nitric oxide synthase activity in human gynecological cancer. Cancer Res 54: 1352-1354, 1994. (Pubitemid 24108080)
18. •OH. Endogenous soluble guanylyl cyclase-activating factors. FEBS Lett 307: 102-107, 1992.
19. Garg UC and Hassid A: Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83: 1774-1777, 1989. (Pubitemid 19124139)
20. Kariya K, Kawahara Y, Araki S, Fukuzaki H and Takai Y: Antiproliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic smooth muscle cells. Atherosclerosis 80: 143-147, 1989. (Pubitemid 20008396)
21. Ambs S, Merriam WG, Ogunfusika MO, Bennett WP, Ishibe N, Hussain SP, Tzeng EE, Geller DA, Billiar TR and Harris CC: p53 and vascular endothelial growth factor regulate tumour growth of NOS2-expressing human carcinoma cells. Nat Med 4: 1371-1376, 1998. (Pubitemid 28553458)
22. Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA and Ziche M: Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 90: 587-596, 1998. (Pubitemid 28204802)
23. Mannick JB, Asano K, Izumi K, Kieff E and Stamler JS: Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell 79: 1137-1146, 1994.
24. Messmer UK, Ankarcrona M, Nicotera P and Brune B: p53 expression in nitric oxide-induced apoptosis. FEBS Lett 355: 23-26, 1994.
25. Hess DT, Matsumoto A, Kim SO, Marshall HE and Stamler JS: Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 6: 150-166, 2005. (Pubitemid 40215810)
26. Kim PK, Kwon YG, Chung HT and Kim YM: Regulation of caspases by nitric oxide. Ann N Y Acad Sci 962: 42-52, 2002.
27. Yu CX, Li S and Whorton AR: Redox regulation of PTEN by S-nitrosothiols. Mol Pharmacol 68: 847-854, 2005.
28. Calmels S, Hainaut P and Ohshima H: Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. Cancer Res 57: 3365-3369, 1997. (Pubitemid 27355476)
29. Raspollini MR, Amunni G, Villanucci A, Boddi V, Baroni G, Taddei A and Taddei GL: Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol Oncol 92: 806-812, 2004. (Pubitemid 38251381)
30. Anttila MA, Voutilainen K, Merivalo S, Saarikoski S and Kosma VM: Prognostic significance of iNOS in epithelial ovarian cancer. Gynecol Oncol 105: 97-103, 2007. (Pubitemid 46442870)
31. Chen HHW, Su WC, Chou CY, Guo HR, Ho SY, Que J and Lee WY: Increased expression of nitric oxide synthase and cyclooxygenase-2 is associated with poor survival in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 63: 1093-1100, 2005. (Pubitemid 41505288)
32. Oka K, Suzuki Y, Iida H and Nakano T: Pd-ECGF positivity correlates with better survival, while iNOS has no predictive value for cervical carcinomas treated with radiotherapy. Int J Radiat Oncol Biol Phys 57: 217-221, 2003. (Pubitemid 36959759)
33. da Silva CS, Michelin MA, Etchebehere RM, Adad SJ and Murta EF: Local lymphocytes and nitric oxide synthase in the uterine cervical stroma of patients with grade III cervical intraepithelial neoplasia. Clinics (Sao Paulo) 65: 575-581, 2010.